Financial reports and accounts

Click any icon listed to display the document. Register for our Alert Service to be notified whenever we add a new report to our website.

Download any document from the list below by clicking on its icon.

Title Audio PDF Powerpoint Webcast
Interim Results 31 Dec 2016      
2016 Notice of Annual General Meeting      
2016 Form of Proxy (specimen) for AGM      
2015/16 Report and Accounts      
Circular for Placing and Notice of General Meeting 
Interim Results 31 Dec 2015      
2015 Notice of Annual General Meeting      
2015 Form of Proxy (specimen) for AGM      
2014/15 Report and Accounts      
2014 H2 Interim Results      
2014 Interim Results      
2014 Notice of Annual General Meeting      
2014 Form of Proxy (specimen) for AGM      
2013 Annual Report  

2013 Interim Results  

2013 Notice of Annual General Meeting      
2013 Form of Proxy (specimen) for AGM      
2012 Annual Report  

2012 Interim Results  

2012 Notice of Annual General Meeting      
2012 Form of Proxy (specimen) for AGM      
Placing and Open Offer February 2012      
2011 Annual Report      

Note: To view PDF files, you will need the Adobe Acrobat Reader. This can be downloaded free of charge from the Adobe website.

Latest News

Vernalis plc receives a $2 million milestone payment from one of its drug discovery collaborations

Vernalis plc announced today that it has received a $2m milestone under one of its existing research collaborations to discover novel small molecules against an undisclosed target utilising Vernalis' fragment and structure-based drug discovery platform.


Read more ...

At a glance

More information on Vernalis and its pipeline ...

FactsheetNov14 Company fact sheet

Comm thumbnail Explore the pipeline ...

Contact Vernalis

T: 0118 938 0000
F: 0118 938 0001

Contact information
Maps and directions
Contact form

To report SUSPECTED ADVERSE REACTIONS, contact Vernalis Therapeutics, Inc. at 1-855-705-9546 and or FDA at 1-800-FDA-1088 or